2000
DOI: 10.1006/viro.2000.0316
|View full text |Cite
|
Sign up to set email alerts
|

Competitive Binding to a Charged Leucine Motif Represses Transformation by a Papillomavirus E6 Oncoprotein

Abstract: E6 oncoproteins from HPV-16 and bovine papillomavirus type 1 (BPV-1) bind to similar leucine-rich peptides termed charged leucine motifs found on the cellular focal adhesion protein paxillin and the E3 ubiquitin ligase E6AP. BPV-1 E6 (BE6) mutants that do not bind to paxillin are defective at inducing cellular transformation. It is possible, however, that BE6 mutants that do not bind paxillin are defective for transformation for an unrelated reason than the ability to bind to charged leucine motifs. To address… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
38
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 40 publications
(40 citation statements)
references
References 17 publications
0
38
0
Order By: Relevance
“…E6 binding to MAML1 is potentially a key determinant of the ability of beta HPVs to replicate in skin, since Notch signaling in keratinocytes promotes differentiation and withdrawal from the cell cycle (41,51). We note that E6AP has been previously reported to bind BPV1 E6 (8,11,66), but we speculate that this interaction was likely due to overexpression of one binding partner or to in vitro artifacts and does not reflect physiological binding in a normal cellular environment.…”
Section: Discussionmentioning
confidence: 76%
“…E6 binding to MAML1 is potentially a key determinant of the ability of beta HPVs to replicate in skin, since Notch signaling in keratinocytes promotes differentiation and withdrawal from the cell cycle (41,51). We note that E6AP has been previously reported to bind BPV1 E6 (8,11,66), but we speculate that this interaction was likely due to overexpression of one binding partner or to in vitro artifacts and does not reflect physiological binding in a normal cellular environment.…”
Section: Discussionmentioning
confidence: 76%
“…Murine C127 and paxillin-null MEFs were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum; assays for anchorage-independent cell growth were performed as previously described (1).…”
Section: Methodsmentioning
confidence: 99%
“…Glutathione S-transferase (GST) and maltose-binding protein (MBP) fusions to BE6 and paxillin and paxillin mutants have been previously described (30). MBP and GST fusions were expressed in Escherichia coli strain BL21(DE3)-RIL and purified onto amylose-Sepharose or glutathione-Sepharose beads as described previously (1).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…C127 cells were reported to contain wild-type p53 (Murphy et al, 1996). Unlike the high-risk HPV E6, BPV-1 E6 does not bind p53 , although it does bind the ubiquitin-protein ligase E6AP that forms a complex with high-risk HPV E6 to degrade p53 (Chen et al, 1995;Bohl et al, 2000). To assess the role of p53 in BPV-1 oncogenes-modulated apoptosis, we established stable cell lines expressing BPV-1 E7 (10.1 PBE7), and E6 plus E7 (10.1 PBE6E7) in the p53À/À mouse fibroblast cell line 10.1 (Murphy et al, 1996).…”
Section: Modulatory Effects Of Bpv-1 E6 and E7 On Fas-mediated Apoptomentioning
confidence: 99%